Abstract: The present disclosure generally relates to viral-based expression systems suitable for the production of molecule of interests in recombinant host cells. The disclosure particularly relates to nucleic acid constructs, such as expression vectors, containing a modified arterivirus genome or replicon RNA in which at least some of its original viral sequence has been deleted. Also included in the disclosure are viral-based expression vectors including one or more expression cassettes encoding heterologous polypeptides. In some embodiments, the expression cassettes are configured and positioned at defined locations on the viral genome so as to enable expression of the heterologous polypeptides in a tunable manner.
Type:
Grant
Filed:
December 4, 2019
Date of Patent:
January 17, 2023
Assignee:
Janssen Pharmaceuticals, Inc.
Inventors:
Kurt Iver Kamrud, Nathaniel Stephen Wang, Martina Felderman, Nancy C. Carrico
Abstract: The present invention relates to macromolecular complexes comprising micron-scale networks which include binding motifs thereon which allow the covalent bonding of the micron-scale networks to particles which provide nanoscale display surfaces. In particular the present invention relates to micron-scale networks of TMV coat proteins comprising a peptide tag (e.g. SpyTag) and particles providing a nanoscale display surface comprising GFP and a corresponding binding protein (e.g. SpyCatcher) wherein the peptide tag and binding protein pair are capable of spontaneously forming a covalent bond.
Type:
Grant
Filed:
May 31, 2018
Date of Patent:
January 10, 2023
Assignee:
The James Hutton Institute
Inventors:
Andrew John Love, Mikhail Emmanuilovich Talianski, Kara McGeachy
Abstract: Described herein are influenza virus-like particles (VLPs) that display on truncated, re-engineered or remodeled HA molecules on their surface. Also described are methods of making and using these VLPs.
Abstract: Disclosed are compositions and methods for the detection of a Flavivirus infection. In some embodiments, the method comprises detecting a recent Flavivirus infection by measuring the amount of anti-NS1 IgG3. In other embodiments, the method comprises detecting a prior Dengue virus infection in a subject previously immunized with a Dengue virus vaccine comprising one or more non-Dengue Flavivirus proteins.
Type:
Grant
Filed:
May 8, 2018
Date of Patent:
December 20, 2022
Assignee:
UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Inventors:
Ernesto Torres De Azeved Marques, Jr., Eduardo Nascimento, Albert Icksang Ko, Donald S. Burke
Abstract: The invention relates to a virus-like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP-based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, chronic, neurological diseases/disorders, asthma, and/or immune-inflammatory diseases/disorders.
Type:
Grant
Filed:
November 22, 2019
Date of Patent:
November 15, 2022
Assignee:
University of Copenhagen
Inventors:
Adam Frederik Sander Bertelsen, Ali Salanti, Thor Theander, Susan Thrane, Christoph Mikkel Janitzek, Mette Ørskov Agerbaek, Morten Agertoug Nielsen, Jan Tobias Gustafsson
Abstract: Modified bacteriophage, uses thereof, and compositions containing the modified bacteriophage are described. The compositions are useful for human treatment and may treat various conditions, including bacterial infections.
Type:
Grant
Filed:
October 8, 2015
Date of Patent:
November 8, 2022
Assignee:
PHICO THERAPEUTICS LTD.
Inventors:
Heather Fairhead, Adam Wilkinson, Katy Pitts, Anne Barnard, Emmanuele Severi, Neil Anderson
Abstract: Methods of determining infection type are disclosed. In one embodiment, the method comprises measuring the amount of a determinant which is set forth in Tables 1 or 2 in a sample derived from the subject, wherein said amount is indicative of the infection type.
Type:
Grant
Filed:
March 2, 2017
Date of Patent:
October 11, 2022
Assignee:
MeMed Diagnostics Ltd.
Inventors:
Kfir Oved, Eran Eden, Olga Boico, Gali Kronenfeld, Roy Navon, Assaf Cohen-Dotan, Einav Simon
Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
Type:
Grant
Filed:
March 10, 2017
Date of Patent:
September 6, 2022
Assignee:
Mayo Foundation for Medical Education and Research
Abstract: A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein and plant lipids. The invention is also directed to a nucleic acid encoding influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.
Abstract: The present disclosure relates to infection-competent, but nonreplicative inactivated modified vaccinia Ankara (MVA) and its use as immunotherapy, alone, or in combination with immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to inducing an immune response in a subject diagnosed with a solid malignant tumor.
Type:
Grant
Filed:
January 31, 2020
Date of Patent:
August 30, 2022
Assignee:
Memorial Sloan Kettering Cancer Center
Inventors:
Liang Deng, Stewart Shuman, Jedd D. Wolchok, Taha Merghoub, Peihong Dai, Weiyi Wang
Abstract: Provided is a platform for of the preparation of improved nucleic acid delivery vehicles, specifically, vehicles having an extended host recognition ability. Further provided are improved vehicles, compositions and uses thereof.
Type:
Grant
Filed:
June 29, 2017
Date of Patent:
August 23, 2022
Assignee:
TECHNOLOGY INNOVATION MOMENTUM FUND (ISRAEL) LIMITED PARTNERSHIP
Abstract: Compositions and methods are disclosed for producing adeno-associated virus (AAV) in insect cells in vitro. Recombinant baculovirus vectors include an AAV Capsid gene expression cassette (Cap), an AAV Rep gene expression cassette (Rep), and a baculovirus homologous region (hr) located up to about 4 kb from a start codon in an AAV expression cassette. Production levels of baculovirus and AAV in insect cells harboring recombinant baculovirus comprising a Cap, a Rep, and an hr are higher compared to controls comprising a Cap and a Rep but no hr. Furthermore, levels of baculovirus and AAV production in insect cells infected with recombinant baculovirus comprising a Cap, a Rep, and an hr are comparatively stable over serial passages of cells, whereas levels of baculovirus and AAV production decline over serial passages of insect cells comprising recombinant baculovirus comprising a Cap and a Rep, but no hr.
Abstract: The present invention concerns methods and compositions for treating or preventing a fungal infection, particularly infection by a Coccidioides species. The invention provides methods and compositions for stimulating an immune response against the fungus. In certain embodiments, the methods and compositions involve a recombinant vaccine.
Type:
Grant
Filed:
March 22, 2019
Date of Patent:
August 16, 2022
Assignees:
Board of Regents, The University of Texas System, The University of Massachusetts
Inventors:
Chiung-Yu Hung, Gary Ostroff, Natalia Castro-Lopez
Abstract: The invention relates to isolated recombinant analogues of flavivirus E-proteins comprising an analogue of a flavivirus E-protein fusion loop, wherein the analogue of the flavivirus E-protein fusion loop comprises at least one glycosylation site for an N-linked glycan that is not present in a natural flavivirus E-protein fusion loop sequence, wherein the at least one glycosylation site is an N-linked glycosylation sequon (Asn-X-Ser/Thr) and the Asn (N) residue of the sequon occupies any of positions 98-110 (DRGWGNGCGLFGK) of the natural flavivirus E-protein fusion loop amino acid sequence, wherein X is any amino acid residue except proline and Ser/Thr denotes a serine or threonine residue for use in an in vitro method for specific detection of anti-flavivirus antibody, diagnosis of flavivirus infection and/or to investigate exposure to flavivirus.
Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
Type:
Grant
Filed:
March 21, 2017
Date of Patent:
August 2, 2022
Assignee:
Bioverativ Therapeutics Inc.
Inventors:
Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
Abstract: This invention is directed to immunogenic composition, conjugates, virus-lie particles (VLP) compositions, vaccines and methods directed to the treatment and/or prevent of infection by Human Papillomavirus.
Abstract: The invention relates to the improvement of endonuclease-based antimicrobials by blocking DNA repair of double-strand break(s) (DSB(s)) in prokaryotic cells. In this respect, the invention especially concerns a method involving blocking DNA repair after a nucleic acid has been submitted to DSB, in particular by a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) associated programmable double-strand endonuclease. The invention particularly relates to the use of an exogenous molecule that inhibits DNA repair, preferably a protein that binds to the ends of the double-stranded break to block DSB repair. The invention also relates to vectors, particularly phagemids and plasmids, comprising nucleic acids encoding nucleases and Gam proteins, and a pharmaceutical composition and a product containing these vectors and their application.
Type:
Grant
Filed:
November 1, 2019
Date of Patent:
June 14, 2022
Assignees:
INSTITUT PASTEUR, ELIGO BIOSCIENCE
Inventors:
David Bikard, Lun Cui, Xavier Duportet, Jesus Fernandez Rodriguez
Abstract: The invention relates, in general, to synthetic chimeric poxviruses, compositions comprising such viruses, and the development and use of systems and methods for producing such synthetic chimeric poxviruses. The synthetic chimeric poxviruses are well suited for live virus vaccines and pharmaceutical formulations.
Abstract: The present invention provides an attenuated African Swine Fever (ASF) virus which lacks a functional version of the following genes: multigene-family 360 genes 9L, 10L, 11L, 12L, 13L and 14L; and multigene-family 505 genes 1R, 2R, 3R and 4R. The invention further provides an attenuated African Swine Fever (ASF) virus which Lacks a functional version of the DP148R gene. The present invention also provides a vaccine comprising such an attenuated virus and its use to prevent ASF. Further, the invention relates to intranasal administration of an attenuated ASF virus.
Type:
Grant
Filed:
October 30, 2019
Date of Patent:
May 17, 2022
Assignee:
THE PIRBRIGHT INSTITUTE
Inventors:
Charles Abrams, Ana-Luisa Reis, Chris Netherton, Linda Dixon, Dave Chapman, Pedro Sanchez-Cordon
Abstract: The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient.
Type:
Grant
Filed:
September 21, 2017
Date of Patent:
May 10, 2022
Assignee:
The Governors of the University of Alberta
Inventors:
Michael Houghton, Abdolamir Landi, Michael Logan, John L. Law, Darren Hockman, Chao Chen